ondansetron

P4, N=40, Active, not recruiting, Instituto Mexicano del Seguro Social | Enrolling by invitation --> Active, not recruiting

After multiple-line treatment including chemotherapy, targeted therapy, and immunotherapy, disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy, and the adverse reactions to the therapy were tolerable.

P=N/A, N=56, Recruiting, Kocaeli University | Not yet recruiting --> Recruiting

P4, N=60, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

P4, N=40, Enrolling by invitation, Instituto Mexicano del Seguro Social | Not yet recruiting --> Enrolling by invitation | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

P1, N=8, Terminated, Hackensack Meridian Health | N=168 --> 8 | Recruiting --> Terminated; Inability to recruit and staffing changes

P3, N=56, Recruiting, University Health Network, Toronto | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

P=N/A, N=188, Not yet recruiting, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Sixth People's Hospital Affiliated to Shangh

P4, N=420, Not yet recruiting, Wang Chenggang(Study sponsor); Shanxi Provincial Hospital of Traditional Chinese Medicine / Shanxi Provincial Institute of Traditional Chinese Medicin

P4, N=100, Not yet recruiting, Liaoning Cancer Hospital and Institute; Liaoning Cancer Hospital and Institute

P=N/A, N=90, Not yet recruiting, Sir Run Run Hospital Affiliated to Nanjing Medical University; Sir Run Run Hospital Affiliated to Nanjing Medical University

P4, N=80, Not yet recruiting, The Second Affiliated Hospital of Guangdong Medical University; The Second Affiliated Hospital of Guangdong Medical University